Introduction

• Evasion of cell-cycle arrest and apoptosis by inactivation of the tumor protein p53 (TP53) is a key mechanism by which tumors promote survival and proliferation1
  – The murine double minute 2 (MDM2) oncoprotein is a critical negative regulator of TP53, and overexpression of this protein aids tumor proliferation1
  – MDM2 gene copy number is increased in an average of 7% of human cancers, and this may be as high as 90% of tumors in some cancer types, such as liposarcoma2,3
• Small molecule inhibitors of the MDM2-p53 interaction (MDM2-p53 antagonists) are being developed as novel anti-cancer drugs
  – Several MDM2-p53 antagonists, designed to restore p53 function in tumors with wild-type p53, are currently in early clinical development4
• BI 907828 is a potent MDM2-p53 antagonist that has shown efficacy in mouse models of human cancer, both with and without MDM2 gene copy number increases

Study design and objectives

• NCT03449381 is a Phase Ia/Ib, open-label, multicenter, dose-escalation trial of BI 907828
• The primary objectives of Phase Ia (dose-escalation) are to determine: maximum tolerated dose (MTD); recommended dose for expansion (RDE); safety and tolerability
• Secondary objectives for Phase Ia include pharmacokinetics (PK) and preliminary anti-tumor activity. Further objectives include pharmacodynamics (PD; GDF-15 induction in plasma)
• The primary objectives of Phase Ib (dose expansion) are to assess the efficacy, safety, and PK profiles at the RDE, and to determine the recommended dose for Phase II

Patients

Key inclusion criteria

- Aged ≥18 years (≥20 years in Japan)
- Pathologically documented advanced/metastatic solid tumor
- Radiologically documented disease progression/relapse during or after all standard of care treatments
- ECOG PS 0–1
- Adequate organ function
- Life expectancy ≥12 weeks at start of treatment
- ≥1 measurable target lesion (for Phase Ib only)

Key exclusion criteria

- Previous administration of any MDM2-p53 antagonist
- Tumor with documented mutation in TP53
- Active or untreated brain metastases (from non-brain tumors)
- Current use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors
- History of bleeding diathesis
- Major surgery within 12 weeks prior to start of study treatment

Endpoints and assessments

<table>
<thead>
<tr>
<th></th>
<th>Phase Ia</th>
<th>Phase Ib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose-limiting toxicities†</td>
<td>Objective response‡</td>
<td></td>
</tr>
<tr>
<td>Maximum tolerated dose†</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Phase Ia</th>
<th>Phase Ib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>Disease control‡</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>PFS‡</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Safety</td>
<td></td>
</tr>
</tbody>
</table>

Key Points

- Patient screening started in June 2018
- The first patient was enrolled in June 2018
- Target enrolment is up to 40 patients in Phase Ia and 50 patients in Phase Ib, across 3 countries

References

5. National Cancer Center Hospital, Tokyo, Japan; 6Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 7Boehringer Ingelheim, Biberach an der Riss, Germany; 8Boehringer Ingelheim Pharmaceuticals, Cambridge, MA, USA; 9Yale Cancer Center, Yale University, New Haven, CT, USA

This study was funded by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version.

*Corresponding author email address: chongc@mskcc.org

Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, May 31 – June 4, 2019

In both phases, treatment will continue until disease progression or unacceptable toxicity